1. Home
  2. OPHC vs MAIA Comparison

OPHC vs MAIA Comparison

Compare OPHC & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo OptimumBank Holdings Inc.

OPHC

OptimumBank Holdings Inc.

N/A

Current Price

$5.73

Market Cap

67.5M

Sector

Finance

ML Signal

N/A

Logo MAIA Biotechnology Inc.

MAIA

MAIA Biotechnology Inc.

HOLD

Current Price

$1.45

Market Cap

79.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OPHC
MAIA
Founded
2000
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
67.5M
79.0M
IPO Year
2012
2022

Fundamental Metrics

Financial Performance
Metric
OPHC
MAIA
Price
$5.73
$1.45
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$6.50
N/A
AVG Volume (30 Days)
37.2K
834.8K
Earning Date
04-24-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
33.33
EPS
0.20
N/A
Revenue
N/A
N/A
Revenue This Year
$17,095.98
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$29.40
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.91
$0.87
52 Week High
$5.90
$3.19

Technical Indicators

Market Signals
Indicator
OPHC
MAIA
Relative Strength Index (RSI) 53.69 58.96
Support Level $5.40 $1.24
Resistance Level $5.90 $1.57
Average True Range (ATR) 0.15 0.08
MACD 0.00 0.01
Stochastic Oscillator 55.26 80.43

Price Performance

Historical Comparison
OPHC
MAIA

About OPHC OptimumBank Holdings Inc.

OptimumBank Holdings Inc serves as a bank holding company for OptimumBank. The Bank provides community banking services to individuals and corporate customers. The services provided by the bank include demand interest-bearing and non-interest-bearing accounts, negotiable order of withdrawal accounts, borrowings, repayment of loans, money market deposit accounts, debit cards, automated teller machines, and other bank related services.

About MAIA MAIA Biotechnology Inc.

MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of targeted immunotherapies for cancer, with an initial focus on non-small cell lung cancer (NSCLC), which represents the majority of lung cancer cases. Its asset, ateganosine (THIO, also known as 6-thio-dG or 6-thio-deoxyguanosine), is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The treatment approach involves administering THIO followed by the immune checkpoint inhibitor Libtayo (cemiplimab), which is manufactured and commercialized by Regeneron.

Share on Social Networks: